Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. CDN Services

We are analyzing https://link.springer.com/article/10.1007/s11060-010-0324-4.

Title:
Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide | Journal of Neuro-Oncology
Description:
Epigenetic silencing of the O6-methylguanine-DNA-methyltransferase (MGMT) gene by promoter methylation is correlated with improved progression-free survival (PFS) and overall survival (OS) in adult patients with newly diagnosed glioblastoma multiforme (GBM) who receive alkylating agents. The aim of this study is to determine the correlation between MGMT and survival in elderly patients with GBM treated with radiotherapy (RT) and temozolomide (TMZ). Eighty-three patients aged 70 years or older with histologically confirmed GBM treated with RT plus TMZ between February 2005 and September 2009 were investigated in this study. The methylation status of the MGMT promoter was determined by polymerase chain reaction analysis. Median PFS and OS were 7.5 and 12.8 months, respectively. The MGMT promoter was methylated in 42 patients (50.6%) and unmethylated in 41 patients (49.4%). Median OS was 15.3 months in methylated patients and 10.2 months in unmethylated patients (P = 0.0001). Median PFS was 10.5 months in methylated tumors and 5.5 months in unmethylated tumors (P = 0.0001). On multivariate analysis MGMT methylation status emerged as the strongest independent prognostic factor for OS and PFS (P = 0.004 and P = 0.005, respectively). The results of the present study suggest that MGMT methylation status might be an important prognostic factor associated with better OS and PFS in elderly patients with GBM treated with RT and TMZ.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

  • Education
  • Science
  • Non-Profit & Charity

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 7,642,828 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don’t know how the website earns money.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com has a revenue plan, but it's either invisible or we haven't found it.

Keywords {🔍}

article, google, scholar, patients, glioblastoma, pubmed, cas, radiotherapy, elderly, temozolomide, mgmt, study, cancer, survival, methylation, oncol, multiforme, promoter, analysis, concomitant, adjuvant, minniti, malignant, neurooncol, treated, access, glioma, privacy, cookies, content, journal, correlation, gene, pfs, newly, diagnosed, status, months, prognostic, hospital, prognosis, engl, med, clin, treatment, department, italy, data, publish, research,

Topics {✒️}

o6-alkylguanine-dna alkyltransferase analysis o6-methylguanine-dna methyltransferase o6-methylguanine-dna-methyltransferase month download article/chapter dna-repair gene mgmt mgmt methylation status improved progression-free survival dna mismatch repair cancer brain tumour full article pdf patients aged 70 years privacy choices/manage cookies methylation status poor prognosis patients important prognostic factor tumor histological type mgmt gene silencing newly diagnosed glioblastoma supratentorial malignant glioma mgmt methylation neuro-oncology aims sant’ andrea hospital phase ii study primary human neoplasia eortc-ncic trial promoter methylation phase ii studies present study suggest high grade glioma gamma knife radiosurgery los angeles county schold sc jr herman jg clinico-therapeutic remarks university “la sapienza” article minniti primary glioblastoma multiforme conditions privacy policy european economic area van der bent population-based description primary temozolomide chemotherapy article journal radiation oncology groups check access instant access accepting optional cookies receive alkylating agents national cancer institute journal finder publish

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide
         description:Epigenetic silencing of the O6-methylguanine-DNA-methyltransferase (MGMT) gene by promoter methylation is correlated with improved progression-free survival (PFS) and overall survival (OS) in adult patients with newly diagnosed glioblastoma multiforme (GBM) who receive alkylating agents. The aim of this study is to determine the correlation between MGMT and survival in elderly patients with GBM treated with radiotherapy (RT) and temozolomide (TMZ). Eighty-three patients aged 70 years or older with histologically confirmed GBM treated with RT plus TMZ between February 2005 and September 2009 were investigated in this study. The methylation status of the MGMT promoter was determined by polymerase chain reaction analysis. Median PFS and OS were 7.5 and 12.8 months, respectively. The MGMT promoter was methylated in 42 patients (50.6%) and unmethylated in 41 patients (49.4%). Median OS was 15.3 months in methylated patients and 10.2 months in unmethylated patients (P = 0.0001). Median PFS was 10.5 months in methylated tumors and 5.5 months in unmethylated tumors (P = 0.0001). On multivariate analysis MGMT methylation status emerged as the strongest independent prognostic factor for OS and PFS (P = 0.004 and P = 0.005, respectively). The results of the present study suggest that MGMT methylation status might be an important prognostic factor associated with better OS and PFS in elderly patients with GBM treated with RT and TMZ.
         datePublished:2010-08-05T00:00:00Z
         dateModified:2010-08-05T00:00:00Z
         pageStart:311
         pageEnd:316
         sameAs:https://doi.org/10.1007/s11060-010-0324-4
         keywords:
            Glioblastoma
            Elderly
            Radiotherapy
            Temozolomide
            MGMT
            Oncology
            Neurology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11060-010-0324-4/MediaObjects/11060_2010_324_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11060-010-0324-4/MediaObjects/11060_2010_324_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11060-010-0324-4/MediaObjects/11060_2010_324_Fig3_HTML.gif
         isPartOf:
            name:Journal of Neuro-Oncology
            issn:
               1573-7373
               0167-594X
            volumeNumber:102
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Giuseppe Minniti
               affiliation:
                     name:Sant’ Andrea Hospital, University “La Sapienza”
                     address:
                        name:Department of Radiation Oncology, Sant’ Andrea Hospital, University “La Sapienza”, Rome, Italy
                        type:PostalAddress
                     type:Organization
                     name:Neuromed Institute
                     address:
                        name:Department of Neurological Sciences, Neuromed Institute, Pozzilli (IS), Italy
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:M. Salvati
               affiliation:
                     name:Neuromed Institute
                     address:
                        name:Department of Neurological Sciences, Neuromed Institute, Pozzilli (IS), Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:A. Arcella
               affiliation:
                     name:Neuromed Institute
                     address:
                        name:Department of Neurological Sciences, Neuromed Institute, Pozzilli (IS), Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:F. Buttarelli
               affiliation:
                     name:Umberto I Hospital, University “La Sapienza”
                     address:
                        name:Department of Pathology, Umberto I Hospital, University “La Sapienza”, Rome, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:A. D’Elia
               affiliation:
                     name:Umberto I Hospital, University “La Sapienza”
                     address:
                        name:Department of Neurosurgery, Umberto I Hospital, University “La Sapienza”, Rome, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:G. Lanzetta
               affiliation:
                     name:Neuromed Institute
                     address:
                        name:Department of Neurological Sciences, Neuromed Institute, Pozzilli (IS), Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:V. Esposito
               affiliation:
                     name:Neuromed Institute
                     address:
                        name:Department of Neurological Sciences, Neuromed Institute, Pozzilli (IS), Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:S. Scarpino
               affiliation:
                     name:Sant’ Andrea Hospital, University “La Sapienza”
                     address:
                        name:Department of Pathology, Sant’ Andrea Hospital, University “La Sapienza”, Rome, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:R. Maurizi Enrici
               affiliation:
                     name:Sant’ Andrea Hospital, University “La Sapienza”
                     address:
                        name:Department of Radiation Oncology, Sant’ Andrea Hospital, University “La Sapienza”, Rome, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:F. Giangaspero
               affiliation:
                     name:Neuromed Institute
                     address:
                        name:Department of Neurological Sciences, Neuromed Institute, Pozzilli (IS), Italy
                        type:PostalAddress
                     type:Organization
                     name:Umberto I Hospital, University “La Sapienza”
                     address:
                        name:Department of Pathology, Umberto I Hospital, University “La Sapienza”, Rome, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide
      description:Epigenetic silencing of the O6-methylguanine-DNA-methyltransferase (MGMT) gene by promoter methylation is correlated with improved progression-free survival (PFS) and overall survival (OS) in adult patients with newly diagnosed glioblastoma multiforme (GBM) who receive alkylating agents. The aim of this study is to determine the correlation between MGMT and survival in elderly patients with GBM treated with radiotherapy (RT) and temozolomide (TMZ). Eighty-three patients aged 70 years or older with histologically confirmed GBM treated with RT plus TMZ between February 2005 and September 2009 were investigated in this study. The methylation status of the MGMT promoter was determined by polymerase chain reaction analysis. Median PFS and OS were 7.5 and 12.8 months, respectively. The MGMT promoter was methylated in 42 patients (50.6%) and unmethylated in 41 patients (49.4%). Median OS was 15.3 months in methylated patients and 10.2 months in unmethylated patients (P = 0.0001). Median PFS was 10.5 months in methylated tumors and 5.5 months in unmethylated tumors (P = 0.0001). On multivariate analysis MGMT methylation status emerged as the strongest independent prognostic factor for OS and PFS (P = 0.004 and P = 0.005, respectively). The results of the present study suggest that MGMT methylation status might be an important prognostic factor associated with better OS and PFS in elderly patients with GBM treated with RT and TMZ.
      datePublished:2010-08-05T00:00:00Z
      dateModified:2010-08-05T00:00:00Z
      pageStart:311
      pageEnd:316
      sameAs:https://doi.org/10.1007/s11060-010-0324-4
      keywords:
         Glioblastoma
         Elderly
         Radiotherapy
         Temozolomide
         MGMT
         Oncology
         Neurology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11060-010-0324-4/MediaObjects/11060_2010_324_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11060-010-0324-4/MediaObjects/11060_2010_324_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11060-010-0324-4/MediaObjects/11060_2010_324_Fig3_HTML.gif
      isPartOf:
         name:Journal of Neuro-Oncology
         issn:
            1573-7373
            0167-594X
         volumeNumber:102
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Giuseppe Minniti
            affiliation:
                  name:Sant’ Andrea Hospital, University “La Sapienza”
                  address:
                     name:Department of Radiation Oncology, Sant’ Andrea Hospital, University “La Sapienza”, Rome, Italy
                     type:PostalAddress
                  type:Organization
                  name:Neuromed Institute
                  address:
                     name:Department of Neurological Sciences, Neuromed Institute, Pozzilli (IS), Italy
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:M. Salvati
            affiliation:
                  name:Neuromed Institute
                  address:
                     name:Department of Neurological Sciences, Neuromed Institute, Pozzilli (IS), Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:A. Arcella
            affiliation:
                  name:Neuromed Institute
                  address:
                     name:Department of Neurological Sciences, Neuromed Institute, Pozzilli (IS), Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:F. Buttarelli
            affiliation:
                  name:Umberto I Hospital, University “La Sapienza”
                  address:
                     name:Department of Pathology, Umberto I Hospital, University “La Sapienza”, Rome, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:A. D’Elia
            affiliation:
                  name:Umberto I Hospital, University “La Sapienza”
                  address:
                     name:Department of Neurosurgery, Umberto I Hospital, University “La Sapienza”, Rome, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:G. Lanzetta
            affiliation:
                  name:Neuromed Institute
                  address:
                     name:Department of Neurological Sciences, Neuromed Institute, Pozzilli (IS), Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:V. Esposito
            affiliation:
                  name:Neuromed Institute
                  address:
                     name:Department of Neurological Sciences, Neuromed Institute, Pozzilli (IS), Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:S. Scarpino
            affiliation:
                  name:Sant’ Andrea Hospital, University “La Sapienza”
                  address:
                     name:Department of Pathology, Sant’ Andrea Hospital, University “La Sapienza”, Rome, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:R. Maurizi Enrici
            affiliation:
                  name:Sant’ Andrea Hospital, University “La Sapienza”
                  address:
                     name:Department of Radiation Oncology, Sant’ Andrea Hospital, University “La Sapienza”, Rome, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:F. Giangaspero
            affiliation:
                  name:Neuromed Institute
                  address:
                     name:Department of Neurological Sciences, Neuromed Institute, Pozzilli (IS), Italy
                     type:PostalAddress
                  type:Organization
                  name:Umberto I Hospital, University “La Sapienza”
                  address:
                     name:Department of Pathology, Umberto I Hospital, University “La Sapienza”, Rome, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Journal of Neuro-Oncology
      issn:
         1573-7373
         0167-594X
      volumeNumber:102
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Sant’ Andrea Hospital, University “La Sapienza”
      address:
         name:Department of Radiation Oncology, Sant’ Andrea Hospital, University “La Sapienza”, Rome, Italy
         type:PostalAddress
      name:Neuromed Institute
      address:
         name:Department of Neurological Sciences, Neuromed Institute, Pozzilli (IS), Italy
         type:PostalAddress
      name:Neuromed Institute
      address:
         name:Department of Neurological Sciences, Neuromed Institute, Pozzilli (IS), Italy
         type:PostalAddress
      name:Neuromed Institute
      address:
         name:Department of Neurological Sciences, Neuromed Institute, Pozzilli (IS), Italy
         type:PostalAddress
      name:Umberto I Hospital, University “La Sapienza”
      address:
         name:Department of Pathology, Umberto I Hospital, University “La Sapienza”, Rome, Italy
         type:PostalAddress
      name:Umberto I Hospital, University “La Sapienza”
      address:
         name:Department of Neurosurgery, Umberto I Hospital, University “La Sapienza”, Rome, Italy
         type:PostalAddress
      name:Neuromed Institute
      address:
         name:Department of Neurological Sciences, Neuromed Institute, Pozzilli (IS), Italy
         type:PostalAddress
      name:Neuromed Institute
      address:
         name:Department of Neurological Sciences, Neuromed Institute, Pozzilli (IS), Italy
         type:PostalAddress
      name:Sant’ Andrea Hospital, University “La Sapienza”
      address:
         name:Department of Pathology, Sant’ Andrea Hospital, University “La Sapienza”, Rome, Italy
         type:PostalAddress
      name:Sant’ Andrea Hospital, University “La Sapienza”
      address:
         name:Department of Radiation Oncology, Sant’ Andrea Hospital, University “La Sapienza”, Rome, Italy
         type:PostalAddress
      name:Neuromed Institute
      address:
         name:Department of Neurological Sciences, Neuromed Institute, Pozzilli (IS), Italy
         type:PostalAddress
      name:Umberto I Hospital, University “La Sapienza”
      address:
         name:Department of Pathology, Umberto I Hospital, University “La Sapienza”, Rome, Italy
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Giuseppe Minniti
      affiliation:
            name:Sant’ Andrea Hospital, University “La Sapienza”
            address:
               name:Department of Radiation Oncology, Sant’ Andrea Hospital, University “La Sapienza”, Rome, Italy
               type:PostalAddress
            type:Organization
            name:Neuromed Institute
            address:
               name:Department of Neurological Sciences, Neuromed Institute, Pozzilli (IS), Italy
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:M. Salvati
      affiliation:
            name:Neuromed Institute
            address:
               name:Department of Neurological Sciences, Neuromed Institute, Pozzilli (IS), Italy
               type:PostalAddress
            type:Organization
      name:A. Arcella
      affiliation:
            name:Neuromed Institute
            address:
               name:Department of Neurological Sciences, Neuromed Institute, Pozzilli (IS), Italy
               type:PostalAddress
            type:Organization
      name:F. Buttarelli
      affiliation:
            name:Umberto I Hospital, University “La Sapienza”
            address:
               name:Department of Pathology, Umberto I Hospital, University “La Sapienza”, Rome, Italy
               type:PostalAddress
            type:Organization
      name:A. D’Elia
      affiliation:
            name:Umberto I Hospital, University “La Sapienza”
            address:
               name:Department of Neurosurgery, Umberto I Hospital, University “La Sapienza”, Rome, Italy
               type:PostalAddress
            type:Organization
      name:G. Lanzetta
      affiliation:
            name:Neuromed Institute
            address:
               name:Department of Neurological Sciences, Neuromed Institute, Pozzilli (IS), Italy
               type:PostalAddress
            type:Organization
      name:V. Esposito
      affiliation:
            name:Neuromed Institute
            address:
               name:Department of Neurological Sciences, Neuromed Institute, Pozzilli (IS), Italy
               type:PostalAddress
            type:Organization
      name:S. Scarpino
      affiliation:
            name:Sant’ Andrea Hospital, University “La Sapienza”
            address:
               name:Department of Pathology, Sant’ Andrea Hospital, University “La Sapienza”, Rome, Italy
               type:PostalAddress
            type:Organization
      name:R. Maurizi Enrici
      affiliation:
            name:Sant’ Andrea Hospital, University “La Sapienza”
            address:
               name:Department of Radiation Oncology, Sant’ Andrea Hospital, University “La Sapienza”, Rome, Italy
               type:PostalAddress
            type:Organization
      name:F. Giangaspero
      affiliation:
            name:Neuromed Institute
            address:
               name:Department of Neurological Sciences, Neuromed Institute, Pozzilli (IS), Italy
               type:PostalAddress
            type:Organization
            name:Umberto I Hospital, University “La Sapienza”
            address:
               name:Department of Pathology, Umberto I Hospital, University “La Sapienza”, Rome, Italy
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Radiation Oncology, Sant’ Andrea Hospital, University “La Sapienza”, Rome, Italy
      name:Department of Neurological Sciences, Neuromed Institute, Pozzilli (IS), Italy
      name:Department of Neurological Sciences, Neuromed Institute, Pozzilli (IS), Italy
      name:Department of Neurological Sciences, Neuromed Institute, Pozzilli (IS), Italy
      name:Department of Pathology, Umberto I Hospital, University “La Sapienza”, Rome, Italy
      name:Department of Neurosurgery, Umberto I Hospital, University “La Sapienza”, Rome, Italy
      name:Department of Neurological Sciences, Neuromed Institute, Pozzilli (IS), Italy
      name:Department of Neurological Sciences, Neuromed Institute, Pozzilli (IS), Italy
      name:Department of Pathology, Sant’ Andrea Hospital, University “La Sapienza”, Rome, Italy
      name:Department of Radiation Oncology, Sant’ Andrea Hospital, University “La Sapienza”, Rome, Italy
      name:Department of Neurological Sciences, Neuromed Institute, Pozzilli (IS), Italy
      name:Department of Pathology, Umberto I Hospital, University “La Sapienza”, Rome, Italy
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(118)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

CDN Services {📦}

  • Crossref

3.56s.